This publication reviews the use of niraparib, an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, for the treatment of advanced ovarian cancer in both the first- and second line setting. Niraparib (Zejula) is licensed in New Zealand for the maintenance treatment of adult patients with advanced or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who have a partial or complete response to platinum-based chemotherapy, and is fully subsidised by PHARMAC for this use (with Special Authority criteria).
Please login below to download this issue (PDF)